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Abstract. We have previously f'ound that a 7-hydroxycoumaiin 
de,ivative h.as potent anti-Helicobacte/'pyloti (H. pylori) activity, 
comparable with metrOnidazole. In this report, we desc/'ibe the 
sti~t.ctural requirement f'or the anti-H. pylori activity of several 
hydrosylated coumalins (1-23). It was found that 7-hydrory-4-
lnethylcoulnalin (6), 6, 7-dihydivxy-4-lnethylcouina!in (8), 6-
hydroxy-7-lnethory-4-methylcou,ncain (1 Q) and 5, 7-dihydroxy-
cyclopentanocoumarin (21) showed comparable anti-H. pyloii 
activity with metlvnidazole. The presence of 7- andlol' 6-hydlvxyl 
groups seems to be esse/7tial to display high,el' anti-H. pylOfi 
activity. Th,eir activities depended on the numbe/~ a/?,d position 
of the hydroxyl ~aroup on the benzenoid i'ing of the coumarin 
system. Methylation of the hydroxy glvup generally diminished 
the activity. In hydr'oxylated coumarins, th,e methyl groLip at C-4 
position enhanced the activity. The inhibitory activity of 
couma7in,s (1-23) against jack bea/7 urease was examined, but 
no coumalins showed any inhibition at 160 /ig/mL. 
Helicobacte," pyloli (H. pylori) is a gram-negative, spiral-
shaped, strongly motile bacterium (1) and is a major 
causative factor of a number of gastric pathologies such as 
gastritis, peptic ulcers and gastric cancers (2). In fact, H. 
pylori is the first bacterium to be classified as a Group 1 
carcinogen and definite cause of gastric cancer in humans 
by the International Agency of Research on Cancer. H. 
pylOi'i urease is considered to be associated with virulence 
(3). Therefore, eradication of the bacteria and inhibition of 
the urease are important for the treatment of patients with 
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gastroduodenal diseases (4). Today, the treatment of this 
infection is mainly based on the use of triple therapies 
consisting of a combination of two antibiotics (amoxicillin, 
clarithromycin and/or m tronidazole) with a proton pump 
inhibitor or bismuth (4). Although these regimens attain 
high cule rates, an eradication failure rate of 5-20% 
remains. A number of problems are also associated with 
multi le th r py, among which are drug resistance, side-
ffects and non-compliance (5). Therefore, the development 
of a new class of inhibitors of H. pylori is urgent. 
I our la oratory, we have initiated the screening of a 
variety of struc urally diverse coumarins to identify a lead 
coumarin with an anti-H. pyloli activity. The studies led to 
the identification of a 7-hydroxycoumarin as a lead molecule 
with anti-H. pylori activity, comparable to the activity of 
metronidazole (6). In this report, we report a follow-up 
structure-activity relationship (SAR) study in which ,the OH-
substituents of coumarins were systematically varied to 
determine the an -H. pylo,i activity. 
M te ials and Methods 
Gen ra . Melting points were determined on an Electrothermal or 
a Buchi B-545 instrument. iH- and 13C-NMR spectra were 
acquired on a Bruker AC 200 or Avance 200 spectrometer (200 
MHZ both) in [D6]DMSO. The chemical shifts refer to TMS (1H-
NMR) or to [D6]DMSO (13C-NMR, 6=39.5 ppm), respectively. 
Combustion analyses were carried out on "Mikroanalytisches Labor 
Hein", Moembris, Germany. TLC (Thin layer chrolnatography) was 
performed on a Merck Kieselgel 60 F254 (Merck 5549, USA). 
Matei'ials. The following chemicals were obtained from each 
indicated company: coumarin (1), 7-hydroxycoumarin (2), 6,7-
dihy roxycoumarin (3), 7-hydroxy-6-methoxycoumarin (4), 7-
hydro y-4-methylcoumarin (6), 6-hydroxy-4-methylcoumarin (7), 
6, 7-dihydrox~f-4-methylcoumarin (8) , 7-methoxy-4-methyl-coum arin 
(12) and 6-methoxy-4-methyl-coumarin (13)(Tokyo Kasei Co., 
Tokyo, J pan); metronidazole and amoxicillin (Wako Pure Chem. 
Ind. Ltd., Japan); clarithromycin (Taisho Pharmaceutical Co., 
0258-851X/2003 $2.00+ .40 509 
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Tokyo, Japan); Dulbecco's modified Eagle medium (DMEM) 
(Gibco BRL, Grand Island, NY, USA); fetal bovine serum (FBS) 
(JRH Biosci., Lenexa, KS, USA). 
Preparation of coumarins (5, 9-11 and 14.23). The following 
coumarins were prepared by the Pechmann reaction (7), unless 
otherwise noted. One equivalent of the (2-substituted) ~-ketoester 
was added dropwise to a solution of the appropriate phenol in 
sulfuric acid (75% in water) at O to 25 ' C. The mixture was kept at 
room temperature for at least 30 minutes and was then placed on 
ice or diluted with ice/water. The product was filtered off and 
recrystallized. 
7-Hydroxy-5,6-dimethoxy-2H-1-benzopyran-2-0ne (5): mp 145= 
146'C (EtOAc/petrol ether). Preparation according to Ahluwalia 
(8). The yield of the last step was 45%. 
5,7-Dihydroxy-4-methyl-2H-1-benzopyran-2-0ne (9) : mp 290-
292'C (EtOH). Yield 72%. IH-NMR (DMSO-d6) 6: 2.50 (d, 3H, 
J=0.9 Hz), 5.85 (q, IH. J=1.0 Hz), 6.18 (d, IH, J=2.4 Hz), 6.27 (d, 
IH. J=2.4 Hz), 10.31 (s, IH), 10.53 (s, IH). 13C-NMR (DMSO-d6) 
6: 23.4 (CH3), 94.5 (CH), 99.1 (CH), 102.1 (C), 108.8 (CH), 155.0 
(C), 156.5 (C), 157.9 (C), 160.1 (C), 161.1 (C). Anal. Calcd for 
CloH804: C, 62.50; H, 4.20. Found: C, 61.94; H, 4.10. 
6-Hydroxy-7-methoxy-4-methyl-2U-1-benzopyran-2-0ne (10) : mp 
212-215 'C (2-propanol)(9). Yield 79%. 
7-Hydroxy-6-methoxy-4-methyl-2H- 1-benzopyran-2-0ne (11) : mp 
217-217.5 'C (EtOH)(9). Yield 66%. 
7-Hydroxy-3-methyl-2H'I-benzopyran-2-0ne (14) : 109 mmol 
methyl formate was added dropwise at 13-15'C to a suspension of 
200 mmol sodium methanolate in 300 mmol propionic acid 
ethylester. After 3.5 hours at room temperature, the solidified 
mixture was diluted with 20 mL methanol. To this solution were 
added 91 mmol resorcin, dissolved in 50 mL methanol, keeping the 
reaction temperature between 14 and 17'C. The mixture was 
stirred at room temperature for 40 hours, acidified with 50 mL 2M 
sulfuric acid (cooling with ice) and diluted with 600 mL water. The 
precipitated product was filtered off, dried and recrystallized; mp 
226-229'C (EtOAC) (10). Yield 31%. *H-NMR (DMSO-d6) ~: 2.04 
(d, 3 H, J=1.2 Hz), 6.71 (d, I H, J=2.4 Hz), 6.77 (dd, I H, J=8.4, 
2.3 Hz), 7.43 (d, I H, J=8.4 Hz), 7.74 (s, I H), 10.40 (s, I H). 13C-
NMR (DMSO-d6) ~: 16.4 (CH3), 101.8 (CH), 111.7 (C), 112.9 
(CH), 119.9 (C), 128.6 (CH), 140.0 (CH), 154.4 (C), 160.1 (C), 
161.6 (C). 
7-Hydroxy-3,4-dimethyl-2H-1-benzopyran-2-0ne (15): mp 265-
270 ' C (2-propanol/EtOH)(11). Yield 82%. 
6,7-Dihydroxy-3,4-dimethyl-2H-1-benzopyran-2-0ne (16) : starting 
material 1,2,4-triacetoxybenzene; mp 267.5-268 ' C (EtOHrrBME)(12). 
Yield 93%. 
6-Hydroxy-7-methoxy-3,4-dimethyl-2H- 1-benzopyran-2-0ne (17) : 
mp 224-226'C (1-propanol/H20, 3/1)(13). Yield 71%. 
7-Hydroxy-6-methoxy-3,4-dimethyl-2H- I -benzopyran-2-0ne (18) : 
mp 198-200'C (EtOH). Yield 68% IH-NMR (DMSO-d6) 6: 2.05 
(s, 3H), 2.36 (s, 3H), 3.86 (s, 3H), 6.74 (s, IH), 7.13 (s, IH), 10.09 
(s, IH). 13C-NMR (DMSO-d6) ~: 12.9 (CH3), 15.1 (CH3), 56.2 
(CH3), 102.6 (CH), 106.9 (CH), 111.8 (C), 117.1 (C), 145.1 (C), 
147.0 (C x 2), 149.9 (C), 161.5 (C). Anal. Calcd for Ci2H1204: C, 
65.45; H, 5.49. Found: C, 65.30; H, 5.48. 
8-Hydroxy-7-methoxy-3,4-dimethyl-2H- I -benzopyran-2-0ne (19) : 
mp 229-230'C (EtOH/H20, 9/1). Yield 66% IH-NMR (DMSO-
d6) 8: 2.07 (s, 3H), 2.33 (s, 3H), 3.88 (s, 3H), 6.99 (d, IH, J=8.9 
Hz), 7.19 (d, IH, J=8.9 Hz), 9.35 (s, IH). 13C-NMR (DMSO-d6) 
~: 12.9 (CH3), 14.9 (CH3), 56.2 (CH3), 108.1 (CH), 114.6 (C), 
114.7 (CH), 117.9 (C), 133.1 (C), 141.0 (C), 147.0 (C), 149.5 (C), 
161.1 (C). Anal. Calcd for Ci2H1204: C, 65.45; H, 5.49. Found: C, 
65.26; H, 5.19. 
2,3-Dihydr0-7,8-dihydr xycyclopentalc][1]benzopyran-4(1H)-
one (20): starting material 1,2,4-triacetoxybenzene; mp 260'C 
(dec., 2-propanol/EtOH). Yield 64%. IH-NMR (DMSO-d6) ~: 
2.07 (quint, 2H, J=7.4 Hz), 2.69 (t, 2H, J=7.4 Hz), 2.96 (t, 2H, 
J=7.6 Hz), 6.77 (s, IH), 6.84 (s, IH), 9.70 (br s, 2H). 13C-NMR 
(DMSO-d6) 6: 22.0 (CH2), 30.0 (CH2), 31.6 (CH2), 102.6 (CH), 
109.3 (CH), 110.1 (C), 122.5 (C), 142.6 (C), 148.2 (C), 149.4 (C), 
156.4 (C), 159.6 (C).Anal. Calcd for C12Hro04: C, 66.05; H, 4.62. 
Found: C, 65.93; H, 4.56. 
2,3-Dihydr0-7,9-dihydroxycyclopenta[c]Lljbenzopyran-4(1H)-
one (21): mp 270-275'C (EtOH/TBME). Yield 96% IH-NMR 
(DMSO-d6) 6: 1.99 (quint, 2H, J=7.6 Hz), 2.60 (t, 2H, J=7.6 
Hz), 3.22 (t, 2H, J=7.6 Hz), 6.20 (d, IH, J=2.2 Hz), 6.25 (d, IH, 
J=2.2 Hz), 10.17 (s, IH), 10.37 (s, IH). 13C-NMR (DMSO-d6) ~: 
22.2 (CH2), 28.9 (CH2), 35.6 (CH_,), 94.,1 (CH), 98.5 (CH), 101.3 
(C), 120.1 (C), 156.3 (C), 156,4 (C), 156.5 (C), 159.4 (C), 160.6 
(C). Anal. Calcd for C12Hr 04: C, 66.05; H, 4.62. Found: C, 
64.13; H, 4.73. 
2,3-Dihydr0-8-hydroxy-7- ethoxycyclopenta[c][1]benzopyran-
4(1H)-one (22): mp 254-255 'C (2-propanol). Yield 71%. IH-NMR 
(DMSO-d6) 6: 2.07 (quint, 2H, J=7.4 Hz), 2.69 (t, 2H, J=7.3 Hz), 
2.95 (t, 2H, J=7.5 Hz), 3.87 (s, 3H), 6.83 (s, IH), 6.98 (s, IH), 9.32 
(br s, IH). 13C-NMR (DMSO-d6) 6: 21.9 (CH2), 30.0 (CH2), 31.5 
(CH2), 55.9 (CH3), 99.8 (CH), 108.9 (CH), 110.8 (C), 123.4 (C), 
143.4 (C), 148.1 (C), 150.9 (C), 156.2 (C), 159.5 (C). Anal. Calcd 
for C13H1204: C, 67.23; H, 5.21. Found: C, 67.30: H, 5.26. 
2,3-Dihydr0-7-hydroxy-8-methoxycyclopentalc][1]benzopyran-
4(1H)-one (23): mp 226.5-227.5'C (EtOHIH20). Yield 52%. IH-
NMR (DMSO-d6) 6: 2.07 (quint, 2H, J=7.3 Hz), 2.70 (t, 2H, J=7.4 
Hz), 3.00 (t, 2H, J=7.6 Hz), 3.83 (s, 3H), 6.79 (s, IH), 6.93 (s, IH), 
10.14 (s, IH). 13C-NMR (DMSO-d6) ~: 22.0 (CH2), 30.0 (CH2), 
31.7 (CH2), 56.1 (CH3), 102.7 (CH), 106.6 (CH), 109.9 (C), 122.6 
(C), 145.1 (C), 149.2 (C), 150.3 (C), 156.6 (C), 159.5 (C). Anal. 
Calcd for C13H1204: C, 67.23; H, 5.21. Found: C, 67.31; H, 5.22. 
Bacteria. H. pylo'i (ATCC43504) was purchased from the American 
Type Culture Collection (Rockville, MD, USA). Jack bean urease 
was obtained from Sigma-Aldrich Co. (St. Louis, MO, USA). 
Measurement of anti-H, pylori activity. The micro-dilution broth 
method was used to determine the minimum inhibitory 
concentration (MIC). rain Heart Infusion (BHI) broth containing 
10% fetal bovine serum (FBS) (Biofluid. Inc., Rockville, MD, 
USA) and 0.1% glucos was used as the medium, and was cultured 
in a jar conditioned with AnaeroPack (Campylo)(Mitsubishi Gas 
Chemical Co., Inc.). Briefly, H. pylori was inoculated in the medium 
and cu]tured at 37'C for 2 days. The collected bacterial colonies 
were diluted to about 107 colony forming unit (CFU)/mL with the 
medium. The fractions were dissolved in DMSO and then diluted 
with the medium. To the solution of the fractions, a suspension of 
bacteria was added to make 106 CFU/150 uL/well. The mixture was 
incubated at 37'C for 5 days. The MIC50 Values of the fractions 
were determined by observation (14). 
Measurement of urease. Although the jack bean urease differs 
somewhat from H. pylori urease (15), this plant source was used 
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for the experiment because of its ready availability. The assay 
mixture, containing 25 uL (4U) of jack bean urease and 25 ~L 
(lOO ~rg) of the test compound, ¥vas preincubated for 30 minutes 
at room temperature in a 96-well assay plate. After 
preincubation, 0.2 mL of 100 mM phosphate buffer pH 6.8 
containing 500 mM urea and 0.002% phenol red were added and 
incubated at room temperature. The reaction time was measured 
by micro plate reader (570 nm), which was the time required for 
enough ammonium carbonate to form to raise the pH of a 
phosphate buffer from 6.8 to 7.7 (16). 
ReSultS and Discussion 
Table I. Evalaat on of anti-H. pylo'i activity of couma'ins. 
R~ R5(.,O(2 :1 
?
R3 R 
1 -23
Among 23 coumarin derivatives (see structural formulae 
in Table I) which had various numbers of hydroxyl and/or 
methoxyl groups at different positions of the benzenoid 
ring of the coumarin system, four compounds (6, 8, 10 
and 21) display potent anti-H. pylOri activity, ranging 
from MIC50 23.0-32.6 ug/mL. The susceptibility of H. 
pylOri to these four coumarins were comparable with that 
of metronidazole. 
Although the anti-H. pyloli activity of the hydroxylated 4-
methylcoumarins did not exhibit any rigid, uniform trend, 
their activies were in the following order; 6,7-dihydroxy = 
7-hydroxy > 6-hydroxy > > 5,7-dihydroxy derivatives. This 
suggests that the hydroxy groups at C-6 and C-7 positions 
are important determinants for the anti-H. pylori activity. 
Methylation of the hydroxy group generally diminished 
the activity, as seen in the following cases of : 6,7-dihydroxy 
(3) vs. 7-hydroxy-6-methoxy (4) ; 7-hydroxy-4-methyl (6) vs. 
7-methoxy-4-methyl (12); 6-hydroxy-4=methyl (7) vs. 6-
methoxy-4-methyl (13); 6,7-dihydroxy-4-methyl (8) vs. 6-
hydroxy-7-methoxy-4-methyl (10) or 7-hydroxy-6-methoxy-
4-methyl (11) and 6,7-dihydroxy-3,4=dimethyl (16) vs. 6-
hydroxy-7-methoxy-3,4-dimethyl (17) or 7-hydroxy-6-
methoxy-3,4-dimethyl (18). These results further support 
the possibility that the hydroxy group is necessary for the 
high potency. 
In hydroxylated coumarins, the methyl group at C-4 
position enhanced the activity. In four 7-hydroxycoumarins, 
the order of potency is 4-methyl (6) > 3,4-dimethyl (15) > 
none (2) > 3-methyl (14). In four 6,7-dihydroxycoumarins, 
the order is 4-methyl (8) > 3,4-dimethyl (16) > none (3) > > 
cyclopenta (20). In four 7-hydroxy-6-methoxycoumarins, the 
order is 4-methyl (11) > none (4) > > 3,4-dimethyl (18), 
cyclopenta (23). In three 6-hydroxy-7-methoxycoumarins, the 
order is 4-methyl (10) > > 3,4-dimethyl (17), cyclopenta (22). 
The inhibitory activity of coumarins (1-23) against jack 
bean urease was examined, but no coumarins showed any 
inhibition at 160 ug/mL, in contrast to acetohydroxamic acid 
(IC50: 3.5 ug/mL). 
In conclusion, we synthesized and evaluated a series of 
hydroxylated coumarin derivatives. It was found that several 
hydroxylated coumarins showed potent anti-H. pylori activity 
Compound R R Rs R4 6 MIC50 (}lg/mL) Rs ?
?
?
?
?
?
?
?
?
?
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
H H H H H H H H H H H CH3 
H CH3 
H CH3 
H CH3 H CHS 
H CH3 
H CH3 H CH3 
CHe H 
CH3 CH3 
CH3 CH3 
CH3 CH3 
CH3 CH3 
CH3 CH3 
-(CH2)3-
-(CH2)3-
-(CH2)3-
-(CH2)3-
Metronid8zole 
AmoxiciM~n 
Clsrtthromycin 
?
?
?
?
OCH3 
?
?
?
OH ?
?
?
?
?
?
?
?
?
?
?
OH?
?
?
OH 
OCH3 
OCH3 
?
OH 
OH 
OH 
OCH3 
OCH3 ?
?
OH 
OH 
OCH3 ?
OH ?
OH 
OCH3 
?
OH 
OH 
OH 
OH 
OH 
?
OH 
OH 
OCH3 
OH 
OCH3 
OH 
OH 
OH 
OCH3 
OH 
OCHe 
OH 
OH 
OCH3 
OH
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
OH ?
?
?
?
>i OO 
57.7 
65.8 
79.7 
69. 1 
28.3 
42.0 
23.0 
>i OO 
32.6 
66.7 
>1 OO 
>i OO 
70.2 
51 .5 
55.0 
>1 OO 
>1 OO 
>i OO 
>1 OO 
28.0 
>1 OO 
>1 OO 
27 . 2 
~ .7 x 10~4 
1 2 x 10~s 
(MIC50=20-30 ug/mL), comparable with metronidazole 
(MIC50=27.2 ug/mL). It is suggested that coumarins 
generally possess moderate anti-H. pylo,i activity and their 
activity strongl  depends on the number and position of the 
hydroxyl group n the benzenoid ring of the coumarin 
system. However, these compounds did not inhibit the jack 
bean urease, suggesting a different mode of their actions 
from the urease inhibitors, omeprazole and rabeprazole (17). 
Some epidemiol gical reports showed that a high intake 
of Allium vegetable  including garlic reduces the risk of 
gastric c ncer (18). Coumarin derivatives are widely 
di ributed in plants and are present in notable amounts in 
citrus fruits and vegetables such as celeriac, parsnip, egg 
plant, fennel leaves, parsley and tomatoes (19). Therefore, 
ingestion of such food could have a protective effect against 
H. pylOl =associated gastroduodenal disease. 
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